Literature DB >> 11519839

Portal vein thrombosis associated with antiphospholipid syndrome.

Y Hirohata1, A Murata, S Abe, M Otsuki.   

Abstract

Portal vein thrombosis is a rare occurrence, and often an underlying hypercoagulable state can be found. Recently, there has been growing interest and recognition of the antiphospholipid syndrome in association with acquired hypercoagulable state. This syndrome consists of the association of lupus anticoagulant or antiphospholipid antibodies with arterial or venous thrombosis, thrombocytopenia, and spontaneous abortion. We report a case of portal vein thrombosis associated with the antiphospholipid syndrome. In our patient, chronic liver disease, hepatobiliary infection, abdominal malignancies, myeloproliferative disorders, and inherited coagulation disorders were excluded. This case report suggests that serum antiphospholipid antibodies should be investigated in patients with portal vein thrombosis of unexplained etiology.

Entities:  

Mesh:

Year:  2001        PMID: 11519839     DOI: 10.1007/s005350170063

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  3 in total

1.  Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies.

Authors:  Mats Ogren; David Bergqvist; Martin Björck; Stefan Acosta; Henry Eriksson; Nils H Sternby
Journal:  World J Gastroenterol       Date:  2006-04-07       Impact factor: 5.742

2.  Portal vein thrombosis in a patient with hepatitis C virus-related cirrhosis complicated with antiphospholipid syndrome.

Authors:  Yohei Kida; Etsuko Maeshima; Yoichi Yamada
Journal:  Rheumatol Int       Date:  2009-01-28       Impact factor: 2.631

3.  A single hospital study on portal vein thrombosis in cirrhotic patients - clinical characteristics & risk factors.

Authors:  Huisong Chen; Goolab Trilok; Fei Wang; Xiaolong Qi; Junjie Xiao; Changqing Yang
Journal:  Indian J Med Res       Date:  2014-02       Impact factor: 2.375

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.